Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz

Antiviral Therapy

Volumn 12, Issue 6, 2007, Pages 963-969

  Pham, Paul A ^a   Hendrix, Craig W ^a   Barditch Crovo, Patricia ^a   Parsons, Teresa ^a   Khan, Wasif ^a   Parish, Michelle ^a   Radebaugh, Christine ^a   Carson, Kathryn A ^a   Pakes, Gary E ^b   Qaqish, Roula ^c   Flexner, Charles ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b GLAXOSMITHKLINE   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; EFAVIRENZ; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; STEADY STATE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CARBAMATES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; PYRIMIDINONES; RITONAVIR; SULFONAMIDES;

EID: 34848826918     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Paulsen D, Liao Q, Fusco G, et al. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Res Hum Retroviruses 2002; 18:1011-1019.
2. De Luca A, Baldini F, Cingolani A, et al. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmaco-dynamics. J Acquir Immune Defic Syndr 2004; 35:359-366.
3. Raguin G, Chêne G, Morand-Joubert L, et al. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther 2004; 9:615-625.
4. Wire MB, Shelton MJ, Studenberg S. Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006; 45:137-168.
5. Wynn Vezina H, Brundage R, Bushman L, Fletcher C. Pharmacologic management of the drug-drug interaction between lopinavir/ritonavir and amprenavir. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Poster 609.
6. Meynard JL, Poirier JM, Guiard-Schmid JB, et al. Impact of ABT 378/r on the amprenavir plasma concentrations in HIV-experienced patients treated by the association of APV - ABT 378/r. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. 16-19 December 2001, Chicago, IL, USA. Abstract 1736.
7. nd International Workshop on Clinical Pharmacology of HIV Therapy. 2-4 April 2001, Noordwijk, the Netherlands. Abstract 1.14.
8. th Conference on Retroviruses and Opportunistic Infections. 24-28 February 2002. Seattle, WA, USA. Abstract 440-W.
9. Mauss S, Scholten S, Wolf E, et al. A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir. HIV Med 2004; 5:15-17.
10. Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2004; 75:310-323.
11. nd Interscience conference on Antimicrobial Agents and Chemotherapy. 27-30 September 2002, San Diego, CA, USA. Abstract A-1823.
12. Turner ML, Reed-Walker K, King JR, Acosta EP. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatog B Analyt Technol Biomed Lif Sci 2003; 784:331-341.
13. Veldkamp AI, van Heeswijk RPG, Meenhorst PL, et al. Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor in human plasma using isocratic reverse-phase high-performance liquid chromatography with ultraviolet detection. J Chromatog B Biomed Appl 1999; 734:55-61.
14. th Conference on Retroviruses and Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract/presentation 178.
15. th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 612.
16. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75:7462-7469.
17. Morse GD, Rosenkranz S, Para MF, et al. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Antimicrob Agents Chemother 2005; 49:3373-3381.
18. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002; 46:746-754.
19. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [updated 2006 October 10; cited 2007 August 3]. Available from http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf
20. Kashuba AD, Tierney C, Downey GF, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 2005; 19:145-152.
21. Kaplan SS, Hicks CB. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection. Expert Opin Pharmacother 2005; 6:1573-1585.